Thursday , October 19 2017
Home / Resources / Articles / Issue 110 Item 9 ADA: The Effect of Orlistat on Glycemic Control Is Independent

Issue 110 Item 9 ADA: The Effect of Orlistat on Glycemic Control Is Independent

Blood glucose improvements independent of weight loss. Orlistat (ORL) in conjunction with a mildly reduced-calorie diet is associated with improvements in glycemic control, lipid profile and blood pressure and significant weight loss in patients with type 2 diabetes (T2D).

The mean change from baseline in body weight was comparable in ORL- and PL-treated patients. However, compared to PL-treated patients, ORL-treated patients had a significantly greater decrease in both HbA1c and FPG (LSM differences were -0.43% and -0.85 mmol/L respectively). A regression analysis demonstrated that the change in glycemic control in ORL-treated patients was significantly less correlated to weight loss than for PL-treated patients.

In conclusion, much of the glycemic improvements in ORL- compared to PL-treated patients are independent effects not related to weight loss. American Diabetes Association’s 62nd Annual Scientific Sessions